#SFHS2608605VNotice on the Decision of the National Union of Health Insurance Funds Setting the Insured's Contribution Rate for Pharmaceutical Specialties
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
The decision sets the insured's contribution rate at 35% for various dosages of the drug YORVIPATH, prescribed to patients in pre-filled injection pens. Pharmaceutical companies and insured patients who use these medications are directly affected. This change may require adjustments in insurance claims processing and patient billing.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- The insured's contribution rate for YORVIPATH set at 35%.
- Applies to different dosages of pre-filled injection pens.
- Affects billing and insurance claims processing.
Obligations
What this law requires
Apply a 35% insured contribution rate to YORVIPATH (palopegteriparatide) 168 mg/0.56 ml solution injectable en stylo prérempli (CIP code 34009302889 8 6)
Apply a 35% insured contribution rate to YORVIPATH (palopegteriparatide) 294 mg/0.98 ml solution injectable en stylo prérempli (CIP code 34009302889 9 3)
Apply a 35% insured contribution rate to YORVIPATH (palopegteriparatide) 420 mg/1.4 ml solution injectable en stylo prérempli (CIP code 34009302890 0 6)
Update insurance claims processing systems to reflect the 35% contribution rate for all three YORVIPATH dosages effective from the decision date of 29 October 2024
Adjust patient billing and cost-sharing calculations to charge insured patients 35% of the medication cost for YORVIPATH prescriptions